TOMI Environmental Solutions Inc. (TOMZ) stock prices were down by 0.38% shortly after market trading commenced on October 5th, 2021. This brought the price per share down to USD$1.30 early on in the trading day.
TOMZ Stock’s Order
October 5th 2021 saw TOMZ stock announce having received a purchase order from a multinational top five pharmaceutical company. The order is for the company’s SteraMist Environment system and validation service, which will be used at a variety of locations. As per ongoing communications with the customer, the company understands that this is an initial order for a new facility. The company also expects additional future follow-on orders for this partner’s multiple locations. These orders will be for multiple of the customer’s locations for both additional environment systems, as well as its Custom Engineered System (CES) across the United States and Europe.
Partner Network Expansion
The company is continuing to expand its network of partnership with large, global pharmaceutical companies. This company’s customer’s continue to expand the use of SteraMist decontamination throughout their numerous facilities. This reflects the many advantages of SteraMist iHP technology that it has to offer. The company is well positioned for follow-on business as it continues to prove the value of its technology and products. TOMZ stock is keen to expand its opportunity to permanently integrate SteraMist iHP technology with the installation and implementation of the CES product line, both domestically and internationally.
Scope of SteraMist
TOMZ stock is continuing to promote its SteraMist brand on a global level, while demonstrating its commitment to disinfection around the world. The company’s partnerships have proven profitable, despite the industry having experienced a pause due to Covid-19. SteraMist ionized Hydrogen Peroxide (iHP) technology produces a non-hazardous, eco-friendly disinfection with no byproducts being produced during the process. This development is guided by the company’s continued focus on corporate responsibility and sustainability initiatives. The company’s partnership with its leading pharmaceutical customer consolidates the work it has done with other established Life Science pharmaceuticals customers such as Pfizer and Catalent.
Future Outlook for TOMZ Stock
The company reported a strong quarter, further consolidated by its receiving a purchase order from a leading pharmaceutical company. TOMZ stock is poised to capitalize on the expanded scope of opportunities afforded by this recent order. Current and potential investors are hopeful that management will be able to effectively leverage the resources at its disposal. This is hoped to facilitate consistent and organic growth in shareholder value over the long term.